Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan-Reference-Cited by-同舟云学术

Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan

Published:2020-04-08 Issue:4 Volume:15 Page:e0231413
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Yang Szu-Chun^ORCID,Lai Wu-Wei,Hsu Jason C.,Su Wu-Chou,Wang Jung-Der^ORCID

Funder

Ministry of Science and Technology, Taiwan

National Cheng Kung University Hospital

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference37 articles.

1. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey;Y Yatabe;J Thorac Oncol,2015

2. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;JC Soria;N Engl J Med,2018

3. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial;K Park;Lancet Oncol,2016

4. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial;L Paz-Ares;Ann Oncol,2017

5. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong;VW Lee;Hong Kong Med J,2014

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimating Taiwan's QALY league table for catastrophic illnesses: Providing real-world evidence to integrate prevention with treatment for resources allocation;Journal of the Formosan Medical Association;2024-05

2. Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review;PharmacoEconomics;2024-03-15

3. Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis;PharmacoEconomics - Open;2023-04-19

4. A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC);Expert Opinion on Pharmacotherapy;2022-07-04